A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Sponsor
Eli Lilly and Company
Study ID
NCT05548231
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3437943 — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.

Key Dates

Start date
Oct 24, 2022
Status verified
Aug 2023
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023

Study Design

Enrollment
32 participants (actual)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3437943
    LY3437943 administered subcutaneously (SC)
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Week 20 ]

Related Studies